<DOC>
	<DOCNO>NCT01898715</DOCNO>
	<brief_summary>This first-in-human study design establish safety tolerability ATR-101 patient advance adrenocortical carcinoma whose tumor progress standard therapy . Information also collect determine long ATR-101 stay blood , effect tumor progression see . Biomarkers ( blood urine test ) determine effect production steroid hormone ( cortisol , aldosterone , estrogen testosterone ) see .</brief_summary>
	<brief_title>Phase 1 Study ATR-101 Subjects With Advanced Adrenocortical Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Adrenal Gland Neoplasms</mesh_term>
	<criteria>18 year ; Clinical confirmation adrenocortical carcinoma locally advance metastatic amendable surgical resection ; Failed decline mitotane ( adjuvant therapeutic ) therapy platinumbased chemotherapy regimen ; Able understand comply protocol requirement ; Willing able provide inform consent . Mitotane level &gt; 5 Use contraindicate concomitant medication Unstable medical condition , judgment investigator , could interfere study procedure data interpretation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adrenocortical carcinoma</keyword>
	<keyword>Adrenal cancer</keyword>
	<keyword>ACC</keyword>
</DOC>